Literature DB >> 24125749

The Wnt/β-catenin pathway in ovarian cancer: a review.

Rebecca C Arend1, Angelina I Londoño-Joshi, J Michael Straughn, Donald J Buchsbaum.   

Abstract

OBJECTIVE: Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause of death from cancer in women in the U.S. Since overall survival remains poor, there is a need for new therapeutic paradigms. This paper will review the Wnt/β-catenin pathway as it relates to epithelial ovarian cancer, specifically its role in chemoresistance and its potential role as a target for chemosensitization.
METHODS: A PubMed search was performed for articles published pertaining to Wnt/β-catenin pathway specific to ovarian cancer. Wnt/β-catenin signaling pathways play an active role in cancer stem cells (CSCs) and carcinogenesis of all ovarian cancer subtypes. Studies also have shown that ovarian CSCs are involved in chemoresistance, metastasis, and tumor recurrence.
RESULTS: Wnt/β-catenin target genes regulate cell proliferation and apoptosis, thereby mediating cancer initiation and progression. The Wnt/β-catenin pathway is one of the major signaling pathways thought to be involved in epithelial-to-mesenchymal transition (EMT). Alterations affecting Wnt pathway proteins on the cell membrane, in the cytoplasm, and in the nucleus have been shown to play important roles in the tumorigenesis of ovarian cancer.
CONCLUSIONS: Wnt signaling is activated in epithelial ovarian cancer. Given the role of the Wnt/β-catenin pathway in carcinogenesis, more pre-clinical studies are warranted to further investigate other Wnt inhibitors in ovarian cancer. The Wnt pathway should also be investigated as a potential target in the development of new drugs for ovarian cancer as a single agent and in combination with chemotherapy or other targeted agents.
© 2013.

Entities:  

Keywords:  Ovarian cancer; Wnt; β-Catenin

Mesh:

Substances:

Year:  2013        PMID: 24125749     DOI: 10.1016/j.ygyno.2013.09.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  180 in total

1.  ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics.

Authors:  Dan Su; Dionyssios Katsaros; Shenhua Xu; Haiyan Xu; Yun Gao; Nicoletta Biglia; Jianguo Feng; Lisha Ying; Ping Zhang; Chiara Benedetto; Herbert Yu
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Hypothyroidism reduces mammary tumor progression via Β-catenin-activated intrinsic apoptotic pathway in rats.

Authors:  C M López Fontana; L E Zyla; F E Santiano; C V Sasso; F D Cuello-Carrión; V Pistone Creydt; M A Fanelli; R W Carón
Journal:  Histochem Cell Biol       Date:  2017-02-13       Impact factor: 4.304

3.  Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.

Authors:  Kun Zhang; Haixing Song; Ping Yang; Xiaozhen Dai; Ya Li; Lan Wang; Jun Du; Kejian Pan; Tao Zhang
Journal:  Cell Prolif       Date:  2015-01-21       Impact factor: 6.831

4.  Inhibition of ovarian cancer proliferation and invasion by pachymic acid.

Authors:  Ai-Hua Gao; Liang Zhang; Xin Chen; Ying Chen; Zhen-Zhen Xu; Ya-Nan Liu; Hong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Robust Score Tests With Missing Data in Genomics Studies.

Authors:  Kin Yau Wong; Donglin Zeng; D Y Lin
Journal:  J Am Stat Assoc       Date:  2019-02-26       Impact factor: 5.033

Review 6.  Ovarian cancer in endometriosis: clinical and molecular aspects.

Authors:  B Lyttle; L Bernardi; M E Pavone
Journal:  Minerva Ginecol       Date:  2014-04

7.  Moderate oxidative stress promotes epithelial-mesenchymal transition in the lens epithelial cells via the TGF-β/Smad and Wnt/β-catenin pathways.

Authors:  Xi Chen; Hong Yan; Ying Chen; Guo Li; Yue Bin; Xiyuan Zhou
Journal:  Mol Cell Biochem       Date:  2021-01-08       Impact factor: 3.396

8.  Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.

Authors:  Andrew C Birkeland; Sarah J Burgin; Megan Yanik; Megan V Scott; Carol R Bradford; Jonathan B McHugh; Scott A McLean; Stephen E Sullivan; Jacques E Nor; Erin L McKean; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2017-03-27

9.  Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Authors:  Jonathan D Boone; Rebecca C Arend; Bobbi E Johnston; Sara J Cooper; Scott A Gilchrist; Denise K Oelschlager; William E Grizzle; Gerald McGwin; Abhishek Gangrade; J Michael Straughn; Donald J Buchsbaum
Journal:  Lab Invest       Date:  2015-12-14       Impact factor: 5.662

10.  HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer.

Authors:  Parul Gupta; Sanjay K Srivastava
Journal:  Mol Oncol       Date:  2014-06-18       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.